Entacapone does not induce conformational changes in liver mitochondria or skeletal muscle in vivo
- 1 January 2002
- journal article
- Published by Elsevier in Experimental and Toxicologic Pathology
- Vol. 54 (1) , 9-14
- https://doi.org/10.1078/0940-2993-00228
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Comparative toxicological study on the hepatic safety of entacapone and tolcapone in the ratJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 2001
- Tolcapone and Hepatotoxic EffectsArchives of Neurology, 2000
- Does the sequence of onset of rigor mortis depend on the proportion of muscle fibre types and on intra-muscular glycogen content?International journal of legal medicine, 1999
- Catechol-O-methyltransferase inhibitors for treatment of Parkinson's diseaseThe Lancet, 1998
- Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson's disease, does not impair mitochondrial energy productionEuropean Journal of Pharmacology, 1997
- Fulminant hepatitisJournal of Hepatology, 1986
- Mitochondrial myopathiesAnnals of Neurology, 1985
- Experimental mitochondrial myopathy produced by in vivo uncoupling of oxidative phosphorylationJournal of the Neurological Sciences, 1975
- Conformational Changes of Mitochondria associated with Uncoupling of Oxidative Phosphorylation in vivo and in vitroNature, 1970
- SUDDEN DEATH FROM DINITROPHENOL POISONINGJAMA, 1934